Docket No. TIP-0058-USPCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Paul Stoffels

Int'l Appln. No.: PCT/EP2004/052028

Serial No.: Unassigned Art Unit: Unassigned

Filed: I.A. September 3, 2004 Examiner: Unassigned

For : COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH

RT INHIBITORS

MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

\boxtimes In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with [] the
first or second After Final Submission, therefore:
Statement in Accordance with §1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth
in §1.17(p).
·
In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:
Statement in Accordance with §1.97(e)
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth
in §1.17(p).
To a second second second second (2) (2) (3) (3) (5)
In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of

Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p). \boxtimes Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith. Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT: In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith. If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request. Copies of only foreign patent documents and nonpatent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). \boxtimes There are no listed references which are not in the English language. The relevance of those listed references which are not in the English language is as follows:

either a Final Action under §1.113 or a Notice of Allowance

under §1.311 but before the payment of the Issue Fee.

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/TIP-0058-USPCT/LAD. This form is submitted in triplicate.

Respectfully submitted,

/Laura A. Donnelly/

Laura A. Donnelly Reg. No. 38,435 Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1729 DATED: February 28, 2006

10/570228

SUBMISSION UNDER MPEP 609 D

Application NumberUnassignedFiling DateFebruary 28, 2006First Named InventorPaul StoffelsGroup Art UnitUnassignedExaminer NameUnassignedAttorney Docket NumberTIP-0058-USPCT

Page 1 of 1

U.S. PATENT DOCUMENTS

			U.S. Patent Docum	nent	
Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Number	Kind Code ² (if known)	Pages, Columns, Lines, where relevant passages or relevant figures appear
· ·					
···					
		 			

FOREIGN PATENT DOCUMENTS

		FOREIGI	Y PATENT	DOCUME	NTS		
Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	Foreign P Office ³	atent Docun	nent KindCode ⁵	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
ATT-10-11-11-11-11-11-11-11-11-11-11-11-11-	i						
	<u>-</u> -				_		
<u> </u>							
<u>.</u>	, .	OTHER PRIOR ART - N					
Examiner 's Initials*	Cite No.1	Include name of the author (in Catitle of the item (book, magazine volume-issue number(s	, journal, s	erial, symp	osium, catalo	g, etc.), date, page(s),	T ²
		International Search Report dated PCT/EP2004/052028.	February	7, 2005 f	or related Inte	ernational Application No.	
			, <u></u> ,_,				
			•				
							<u> </u>

Examiner	Date	
Signature	Considered	

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

Application Number	Unassigned > / U
Filing Date	February 28, 2006
First Named Inventor	Paul Stoffels
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	TIP-0058-USPCT

U.S. PATENT DOCUMENTS

		U.S. Patent Do	cument			
Examiner Initials	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
				·		
. <u> </u>						

FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS

		Foreign	Patent Documer	nt	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. ¹	Office ³	Nu mber ⁴ Kir	ndCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ⁶
		wo	03/016306	A 1	Janssen Pharmaceutica N.V.	02-27-2003		
101								

Examiner Date			 	
	Examiner	Date		-
- Serio de l'estate de l'estat	Signature	Considered		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Under the Paperwork Reduction Act of 1995, no persons are required to respond	d to a collection of information unless it displays	a valid OMB control number
form 1449A/PTO	Application Number	Unassigned/
	Filing Date	February 28, 2006
DRMATION DISCLOSURE	First Named Inventor	Paul Stoffels
TEMENT BY APPLICANT	Group Art Unit	Unassigned
	Examiner Name	Unassigned
(use as many sheets as necessary) Sheet 2 of 2	Attorney Docket Number	TIP-0058-USPCT

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	•
Examiner's nitials*	Cite No. ¹	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Pavia, Andrew T., "Abacavir/Lamivudine in Combination With Efavirenz, Amprenavir/Ritonavir or Stavudine", Internet Article, 'Online!, July 9, 2002, XP002274550	
		Young, Benjamin, "Can Abacavir Be Given Once-a-Day?", Internet Article, 'Online!, September 16, 2003, XP002274551	
		Gilead Sciences Inc., "Gilead initiates study 934, a 48-week clinical trial evaluating Viread and Emtriva versus Combivir Internet Article, 'Online!, August 11, 2003, XP002314669	
		Squires, Kathleen E., "An introduction to nucleoside and nucleotide analogues", Antirviral therapy, vol. 6, suppl. 3, pages 1-14 (1001) (XP009042950)	
	-		
			-
		•	
		•	

			
Examiner		Date	· · · · · · · · · · · · · · · · · · ·
		24.0	
Signature		Considered	
		Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.